

Developed under the direction and sponsorship of Shire Pharmaceuticals. Contains promotional material.

Daytrana - ADHD Treatment That Sticks

FOR YOUR PATIENTS

Taking Care of the Skin They're In: Expert Advice About Daytrana and Children's Skin
PDF Download

Dr. Sharon Jacob

Director, Contact Dermatitis Clinic of the University of Miami-Miller School of Medicine and Assistant Professor, Clinical Dermatology, Department of Dermatology and Cutaneous Surgery; President, Florida Contact Dermatitis Society and a consultant for Shire US Inc.

Full Prescribing Information

Important Safety Information

ADHDSupport.com

Shire: Your ADHD Support Company™

ABOUT DAYTRANA

Daytrana™: the Methylphenidate Patch

The next evolution in the delivery of methylphenidate (MPH).

HOW THE PATCH WORKS

Advanced MPH Delivery Using DOT Matrix™ Patch Technology

DOT Matrix patch technology combines MPH and adhesive in a single layer designed for excellent adhesion, providing continuous delivery for smooth levels of medication.

Learn More About How the DAYTRANA PATCH Works

View a video animation of how the DAYTRANA Patch works.

Click to launch

HOW WELL THE PATCH WORKS

Day-Long Control

Efficacy from the first time point measured (2 hours) through 12 hours with the recommended 9-hour wear time.

WHAT IS THE SAFETY PROFILE?

Tolerability Typical of MPH Products

Commonly reported adverse events (AEs) were generally mild to moderate and consistent with those associated with MPH.

HOW TO PRESCRIBE

Individualized Treatment and Wear-Time Flexibility

Dose titration, final dosage, and wear time—up to 9 hours—may be individualized to meet the changing daily needs of patients and parents.

Flexible Dosing Options

Patches are available in packages of 10 and 30.

HOW TO APPLY AND REMOVE

Application and Removal

The Patch is clear, thin, and designed to be easy to apply.

Important Safety Information

Daytrana should not be used in patients with allergy to methylphenidate or patch components; marked anxiety, tension and agitation; glaucoma; tics, diagnosis or a family history of Tourette's syndrome; seizures; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD. Physicians should take a careful patient history, including family history, and physical exam to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.

New psychosis, mania, aggression, growth suppression, and visual disturbances have been associated with the use of stimulants. Use with caution in patients with a history of: psychosis; EEG abnormalities; bipolar disorder; depression. Growth and hematologic monitoring is advised during prolonged treatment. Patients should avoid applying external heat to the Daytrana patch. Erythema has been commonly reported. Contact sensitization may occur.

Daytrana should be given cautiously to patients with a history of drug dependence and alcoholism. Chronic abuse can lead to marked tolerance and psychological dependence. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder.

Common adverse events reported by patients who received Daytrana in clinical trials were decreased appetite, insomnia, nausea, vomiting, decreased weight, tics, affect lability, and anorexia, consistent with adverse events commonly associated with the use of methylphenidate.

^†McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006;9:476-485.

Link to Full Prescribing Information | Important Safety Information | DAYTRANA.com | ADHDSupport.com

©2007 Shire US Inc., Wayne, PA 19087-5367 (800) 828-2088. All rights reserved.
This site is for US residents only.
D887 12/07